Global Sarcopenia Market Analysis: Key Players, Nutritional Therapeutics vs. Clinical Pipeline & CAGR Growth

 

Global Sarcopenia Market Size was valued at USD 2.28 billion in 2025 and is projected to grow to USD 5.63 billion by 2034, with a CAGR of 10.6%.

Sarcopenia Market: Overview

Sarcopenia Market comprises pharmaceutical treatments, nutritional products, diagnostic technologies, rehabilitation services, and supportive healthcare solutions aimed at addressing sarcopenia, a condition characterized by the progressive loss of skeletal muscle mass, strength, and physical performance. The market includes nutritional supplements containing protein, essential amino acids, and vitamin D, alongside diagnostic tools for assessing muscle strength, body composition, and physical function. It also encompasses clinical assessment services, physical rehabilitation programs, resistance exercise solutions, and emerging drug development initiatives targeting muscle degeneration and related biological pathways. These products and services are relevant to older adults, individuals with chronic diseases, patients recovering from hospitalization, and people at increased risk of mobility limitations.

Key Insights

• As per the analysis shared by our research analyst, the global Sarcopenia market is estimated to grow annually at a CAGR of around 10.6% over the forecast period (2026-2034).
• In terms of revenue, the global Sarcopenia market size was valued at around USD 2.28 billion in 2025 and is projected to reach USD 5.63 billion by 2034.
• The market is driven by the accelerating global aging population, rising adoption of nutritional supplements, and advancements in pharmacologic therapies targeting muscle anabolic pathways.
• Based on the Treatment Type, the Protein Supplements segment dominated the market with a share of 55.27% due to its widespread adoption in post-fracture care, institutional settings, and as a first-line intervention for muscle maintenance.
• Based on the Route of Administration, the Oral segment dominated the market with a share of 84.78% owing to its convenience for community-dwelling seniors and standard use in retail and discharge packs.
• Based on the Distribution Channel, the Hospital Pharmacies segment dominated the market with a share of 43.79% because of discharge prescriptions and formulary control in inpatient settings.
• Based on the End User, the Hospitals segment dominated the market with a share of 42.89% as it serves as the primary site for severe case diagnosis and initial treatment interventions.
• Based on the Patient Type, the Primary Age-Related Sarcopenia segment dominated the market with a share of 64.37% as it represents the core age-related muscle loss driving baseline demand.
• Based on region, Asia-Pacific dominated the market with a share of 36.89% attributed to national insurance coverage for screening and nutrition in countries like Japan and South Korea, coupled with rapid demographic aging in China.

Key Growth Drivers & Industry Challenges

Primary Growth Drivers:

• Escalating global population of adults aged 65 and older facing progressive age-related muscle attrition.
• Pipeline breakthroughs in targeted anabolic pathways, myostatin inhibitors, and neuromuscular therapies.
• Increased recognition of sarcopenia as an independent, reimbursable disease code (ICD-10-CM M62.84).

For More Information or queries, Visit @ https://www.fnfresearch.com/sarcopenia-market

Industry Challenges:

• Complete lack of currently approved disease-modifying targeted drugs, creating high dependency on non-prescription oral supplements.
• Heterogeneity in geriatric populations and complex co-morbidities (such as sarcopenic obesity and cancer cachexia) complicating clinical trial endpoints.

Competitive Analysis

The global Sarcopenia market is dominated by players:

• Abbott
• Nestlé Health Science
• Scholar Rock
• Keros Therapeutics
• VERU
• BIOPHYTIS - Live Healthier Longer
• Lipocine Inc.
• ImmunoForge
• Rejuvenate Biomed
• BPGbio, Inc.
• Novartis

Regional Market Dynamics: Asia-Pacific Velocity vs. Western Clinical Development

• Asia-Pacific (Fastest-Growing Region): Holding over 36% of global market revenue, APAC leads growth due to rapid population aging in Japan, China, and South Korea, combined with high public health prioritization of super-aging demographics.
• North America (Dominant Revenue Share): Driven by high healthcare expenditure, strong adoption of premium medical nutrition (such as Abbott and Nestlé medical food formulations), and active clinical trial hubs for first-in-class sarcopenia drug candidates.
• Europe: Heavily focused on multicountry research initiatives funded by Horizon Europe, standardized screening protocols across statutory health schemes, and strict clinical trial frameworks for anti-frailty interventions.